180 Wealth Advisors LLC Reduces Stock Position in Pfizer Inc. (NYSE:PFE)

180 Wealth Advisors LLC lowered its holdings in Pfizer Inc. (NYSE:PFE) by 1.1% in the 2nd quarter, HoldingsChannel reports. The firm owned 32,800 shares of the biopharmaceutical company’s stock after selling 364 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Pfizer were worth $1,202,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. BancFirst Trust & Investment Management lifted its position in shares of Pfizer by 2.3% during the first quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 398 shares during the last quarter. Strategic Investment Advisors MI grew its stake in shares of Pfizer by 32.1% during the first quarter. Strategic Investment Advisors MI now owns 94,117 shares of the biopharmaceutical company’s stock worth $3,840,000 after acquiring an additional 22,879 shares during the last quarter. State of Michigan Retirement System increased its holdings in shares of Pfizer by 0.9% during the first quarter. State of Michigan Retirement System now owns 1,771,584 shares of the biopharmaceutical company’s stock valued at $72,281,000 after acquiring an additional 15,900 shares in the last quarter. MainStreet Investment Advisors LLC raised its position in shares of Pfizer by 1.6% in the 1st quarter. MainStreet Investment Advisors LLC now owns 197,477 shares of the biopharmaceutical company’s stock valued at $8,057,000 after purchasing an additional 3,099 shares during the last quarter. Finally, Center For Asset Management LLC boosted its stake in Pfizer by 28.0% in the 1st quarter. Center For Asset Management LLC now owns 23,894 shares of the biopharmaceutical company’s stock worth $975,000 after purchasing an additional 5,228 shares in the last quarter. 68.05% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 1.3 %

PFE stock opened at $33.64 on Tuesday. The company has a current ratio of 2.12, a quick ratio of 1.82 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average is $35.80 and its 200 day moving average is $37.96. The stock has a market cap of $189.93 billion, a price-to-earnings ratio of 8.95, a PEG ratio of 1.14 and a beta of 0.59. Pfizer Inc. has a 12-month low of $33.44 and a 12-month high of $54.93.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.10. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $13.36 billion. Pfizer had a net margin of 27.55% and a return on equity of 28.36%. Pfizer’s quarterly revenue was down 54.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.04 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 3.33 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th were given a dividend of $0.41 per share. The ex-dividend date of this dividend was Thursday, July 27th. This represents a $1.64 annualized dividend and a dividend yield of 4.88%. Pfizer’s payout ratio is 43.62%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $75.00 target price on shares of Pfizer in a research note on Monday. Barclays decreased their target price on Pfizer from $40.00 to $38.00 in a report on Tuesday, July 11th. Credit Suisse Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $47.00 to $40.00 in a report on Thursday, June 29th. StockNews.com initiated coverage on shares of Pfizer in a report on Thursday, August 17th. They issued a “hold” rating on the stock. Finally, Truist Financial reissued a “buy” rating and set a $62.00 target price on shares of Pfizer in a report on Wednesday, September 13th. Twelve analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $46.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.